Diabetes, Parkinson's disease
Air pollution increases your risk of Parkinson’s disease by 56%, study finds
Parkinson's disease (PD) affects about 2% of people aged 70 and older. Over the next 20 years, the number of individuals with PD is expected to triple. There are various theories explaining this increase,
Could gut problems increase your risk of Parkinson's disease? New research points to yes
A study found that those with upper gastrointestinal damage are 76% more likely to develop Parkinson's disease, signaling a potential paradigm shift in how the disease is studied.
Exposure to Air Pollution Linked to Increased Risk of Parkinson's Disease
Increased exposure to air pollution in the form of particulate matter with a diameter of 2.5 µm or less (PM2.5) and nitrogen dioxide (NO2) was associated with a higher risk for Parkinson's disease, according to a population-based case-control study in JAMA Network Open.
Scientists studying ‘Parkinson’s belt’ believe disease is linked to chemicals
The “Parkinson’s Belt” is a series of regions in the U.S. with unusually high rates of the disease. Some scientists believe that environmental factors play a major role in who gets Parkinson’s.
Study finds genetic link between Parkinson's disease, ALS
People with rare genetic variants linked to degenerative brain disorders like Parkinson's disease are at increased risk of developing ALS, a new study finds.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Air pollution exposure increases risk for Parkinson's disease
Higher exposure to air pollution increases the risk for Parkinson's disease (PD), according to a study published online Sept. 16 in JAMA Network Open.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Research shows diabetes drug could reduce dementia risk. Here’s how the two diseases may be linked
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
Some diabetes medications linked to lower dementia, Parkinson's disease risk
Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.
How a Colorado Parkinson’s group uses climbing to help stave off effects of the disease
Paul Stroud’s done everything he can to combat the effects of Parkinson’s disease. He had a pair of stimulators implanted ...
Are environmental toxins be behind NZ’s alarming increase in Parkinson’s Disease?
Parkinson’s disease is the world’s fastest-growing neurological disease and pesticide exposure may be a factor. Is New ...
New study to investigate non-invasive treatment for dementia and Parkinson’s
A first-of-its-kind study will use ultrasound and light therapies to investigate targeted treatment of Alzheimer’s disease, ...
TAG24 NEWS on MSN6d
Tests show seaweed could help against Parkinson's disease
Eating seaweed could help prevent Parkinson’s disease, according to researchers in Japan, where the highly nutritious plant ...
News Medical5d
New microscopy technique detects early Parkinson's disease indicators
Researchers at Tel Aviv University cooperated with three major Israeli medical centers to develop a new method for detecting ...
WMNF2d
USF researcher integral part of FDA’s approval of new Parkinson’s drug
The cause of Parkinson's Disease remains largely unknown, but a new drug could be extremely beneficial to treat symptoms.
Novel drug molecule could help treat Parkinson's disease in young patients
More than 100,000 Canadians currently live with Parkinson's disease. A novel drug molecule being studied by researchers from ...
Optimistic Buy Rating for Gain Therapeutics’ GT-02287 Based on Promising Parkinson’s Disease Treatment Potential
Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...